United Therapeutics (NASDAQ:UTHR – Get Rating) posted its earnings results on Wednesday. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.10 by ($1.69), Briefing.com reports. United Therapeutics had a net margin of 35.27% and a return on equity of 15.82%. The company had revenue of $466.90 million during the quarter, compared to analysts’ expectations of $461.06 million. During the same quarter last year, the firm earned $3.65 EPS. United Therapeutics’s revenue for the quarter was up 4.6% on a year-over-year basis.
United Therapeutics Price Performance
Shares of UTHR stock opened at $221.65 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.54 and a current ratio of 8.84. United Therapeutics has a fifty-two week low of $158.38 and a fifty-two week high of $245.48. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 4.22 and a beta of 0.53. The stock’s 50-day simple moving average is $230.64 and its 200-day simple moving average is $203.12.
Analysts Set New Price Targets
UTHR has been the topic of several analyst reports. Jefferies Financial Group lifted their target price on United Therapeutics from $223.00 to $245.00 in a research note on Tuesday, May 24th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $225.00 to $238.00 in a research note on Tuesday, May 24th. Credit Suisse Group boosted their price target on United Therapeutics from $219.00 to $247.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 24th. Finally, Oppenheimer boosted their price target on United Therapeutics from $275.00 to $300.00 in a research note on Thursday, May 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $250.14.
Insider Buying and Selling
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of UTHR. Wellington Management Group LLP lifted its holdings in United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after acquiring an additional 710,668 shares during the period. State Street Corp lifted its holdings in United Therapeutics by 7.2% in the first quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock valued at $291,809,000 after acquiring an additional 109,226 shares during the period. Mackenzie Financial Corp lifted its holdings in United Therapeutics by 183.6% in the first quarter. Mackenzie Financial Corp now owns 43,654 shares of the biotechnology company’s stock valued at $7,832,000 after acquiring an additional 28,260 shares during the period. Prudential Financial Inc. lifted its holdings in United Therapeutics by 29.7% in the first quarter. Prudential Financial Inc. now owns 92,056 shares of the biotechnology company’s stock valued at $16,516,000 after acquiring an additional 21,057 shares during the period. Finally, Walleye Capital LLC lifted its holdings in United Therapeutics by 1,012.0% in the first quarter. Walleye Capital LLC now owns 22,341 shares of the biotechnology company’s stock valued at $4,008,000 after acquiring an additional 20,332 shares during the period. 94.68% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.